ACE Inhibitor, Echocardiogram and Research

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

ACE Inhibitor

Echocardiogram

Research

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

DAIC

APRIL 9, 2024

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. The mean dose of enalapril among those who were randomized to take the ACE inhibitor was 17.7mg.

ACE Inhibitor

ACE Inhibitor Cancer Biomarkers Heart Failure

Upon arrival to the emergency department, a senior emergency physician looked at the ECG and said "Nothing too exciting."

Dr. Smith's ECG Blog

NOVEMBER 30, 2022

Here is the cath report: Echocardiogram: There is severe hypokinesis of entire LV apex and apical segment of all the walls. Contemporary research studies of MINOCA have evaluated the prognosis of these patients, reporting a 12-month all-cause mortality of 4.7% (95% confidence interval, 2.6–6.9), Lindahl et al.

Plaque

Plaque Chest Pain Thrombosis Stenosis

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Cardiovascular Update

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

Upon arrival to the emergency department, a senior emergency physician looked at the ECG and said "Nothing too exciting."

Webinars

Stay Connected